The results of the SURMOUNT-1 clinical study of tepoxetine were published in the authoritative journal "The New England Journal of Medicine". Tirzepatide can help patients lose weight continuously throughout the treatment period. At the end of the 72-week treatment period, the average weight loss of adults receiving a 15mg dose was 20.9%.
.jpg)
Using Tirzepatide: 75% of the weight loss comes from fat mass and 25% from fat-free mass, which is significantly more effective. Compared with the previous generation of products, 61% of the weight loss comes from fat mass and 39% from fat-free mass.
Tirzepatide mimics the effects of GLP-1, increasing insulin secretion after meals while inhibiting glucagon release in the liver and reducing glucose production. It also slows gastric emptying and prolongs satiety. As a new target, GIP enhances insulin secretion and improves fat metabolism. Its combined action with GLP-1 helps improve the overall efficacy.
